Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy

Inclusion Criteria: * Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I,II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II-III) OR patients with documented silent ischemia, all treated with a second generation drug eluting stent * Presence of one or more de novo stenosis equal or greater than 70% in a native coronary artery, treated with a Resolute drug eluting stent * Patient is \> 18 years of age (or minimum age as required by local regulations). * The patient has consented to participate by signing the "Patient Informed Consent Form"" * The patient is willing and able to cooperate with study procedures and required follow up visits * Any type of lesion or number of lesion can be included in this trial unless specifically detailed in the exclusion criteria. * At least one second generation DES implanted in the target lesion in the last 24 hours * No other DES implanted before the target procedure * No BMS implanted in the 12 months before the target procedure Exclusion Criteria: * Patients treated for lesions in venous or arterial grafts * Patients treated for in-stent restenosis * Patients treated for Unprotected Left Main lesions * ST elevation myocardial infarction in the 48 hours prior to the procedure * Non ST elevation myocardial infarction * Patients with LVEF≤30% * Women with known pregnancy or who are lactating * Patients with hypersensitivity or allergies to hepari, or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast media. * Patients with chronic renal insufficiency * Contraindication to the use of clopidogrel and/or ASA: * History of drug allergy to thienopyridine derivatives or ASA * History of clinically significant or persistent thrombocytopenia or neutropenia * Active bleeding or significant risk of bleeding, such as elderly patients receining fibrinolytic therapy and other potent antithrombotic agents, severe hepatic insufficiency, current peptic ulceration, proliferative diabetic retinopathy * Uncontrolled hypertension * Current medical condition with a life expectancy of less than 24 months. * The subject is participating in another device or drug study * Subject must have completed the follow-up phase of any previous study at least 30 days prior to enrolment in this trial. * Patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits participation in this study